淋巴瘤临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 淋巴瘤（国际通用名 lymphoma）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖霍奇金淋巴瘤、非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤、DLBCL等说法。

正在招募的淋巴瘤新药试验

• Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia

  不适用招募中澳大利亚意大利NetherlandsSwitzerlandNCT06166706

• Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  II 期招募中西班牙NCT06544785

• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT04002947

• Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

  III 期招募中中国NCT06496308

• Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma

  不适用招募中中国NCT06795113

• Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

  I 期招募中中国NCT06690827

• The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

  不适用招募中美国NCT05876923

• Autonomic Involvement in Patient With Cognitive Decline

  不适用招募中意大利NCT06292741

• Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

  早期 I 期招募中中国NCT06633341

• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

  II 期招募中美国NCT06043323

• Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

  II 期招募中美国NCT05519579

• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

  II 期招募中中国NCT05933967